Grifols, S.A. (NASDAQ:GRFS) Given Consensus Recommendation of “Hold” by Analysts

Shares of Grifols, S.A. (NASDAQ:GRFS) have received a consensus rating of “Hold” from the five analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and one has given a buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $10.00.

A number of analysts recently weighed in on the company. Zacks Research downgraded Grifols from a “hold” rating to a “strong sell” rating in a research note on Friday, December 5th. JPMorgan Chase & Co. reduced their target price on Grifols from $10.30 to $10.00 and set a “neutral” rating for the company in a report on Monday, December 8th. Weiss Ratings restated a “hold (c)” rating on shares of Grifols in a research report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Grifols from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 15th.

Grifols Stock Performance

Shares of GRFS opened at $8.91 on Thursday. The stock has a market capitalization of $6.13 billion, a P/E ratio of 46.89, a P/E/G ratio of 0.37 and a beta of 0.67. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.93 and a current ratio of 2.48. Grifols has a 1 year low of $6.19 and a 1 year high of $11.14. The company’s fifty day moving average is $9.00 and its two-hundred day moving average is $9.45.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Brandes Investment Partners LP increased its stake in Grifols by 8.9% in the 2nd quarter. Brandes Investment Partners LP now owns 28,035,461 shares of the biotechnology company’s stock valued at $253,441,000 after purchasing an additional 2,294,113 shares in the last quarter. Vinva Investment Management Ltd purchased a new stake in Grifols during the second quarter worth $256,000. Norges Bank acquired a new stake in Grifols in the second quarter valued at $17,538,000. Vestmark Advisory Solutions Inc. purchased a new position in shares of Grifols in the second quarter valued at $414,000. Finally, State of Wyoming purchased a new position in shares of Grifols in the second quarter valued at $1,729,000.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.